Next Phase Newsletter

A venture capital investor with more than $1 billion in funding that helps founders bring therapeutic ideas to clinical proof-of-concept in a capital-efficient model. The firm provides portfolio companies with both capital and access to an experienced team of drug developers and biotech operators who deliver tailored operational and scientific support. 

The firm invests in therapeutics companies at the Seed ($5–12 million) or Series A ($15–25 million) stage and is also open to spinout opportunities. The firm can be first or second money in and is geography-agnostic. 

The firm solely invests in therapeutics and is modality- and indication-agnostic. Companies can be single-asset or platform-focused. The firm will fund anything from a well-defined idea on paper to existing companies with significant proof-of-concept data or early clinical data. 

The firm does not have specific management team requirements and typically acts as a lead investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A seed and early-stage venture investor and invests in disruptive technologies with focus on highly scalable Health Tech and ICT models. The typical investment size ranges from €0.5 million to € 5 million. The firm invests only in companies based in Europe. 
 
The firm is currently looking for new opportunities and focuses on companies developing biotech enabling platforms, diagnostics, digital health solutions and minimally to non/minimal-invasive medical devices. The firm will not invest in pure drug development companies without underlying platform technology. 
 
The firm typically seeks to invest in private companies with convincing founder teams. The firm will consider pre-revenue companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital fund makes equity investments ranging from €500,000 to €5 million, with additional capital reserved for follow-on financing. The firm invests in companies across Europe and selectively in the United States. 

The firm is currently seeking opportunities in the sectors of BioTools, Labtech, TechBio, Medical Technology, Biotech, and Diagnostics. The firm prefers companies that have already established proof of concept. 

The firm focuses on privately held companies and does not require high-profile management teams to be in place. The firm generally takes a board seat following investment and prefers to act as the lead investor. The firm targets companies that already have a commercially viable technology, product, or service, ideally with a first collaboration or pilot with a potential customer, and that can reach commercialization with total investment between €10 million and €50 million. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm based in the US manages close to $1B assets under management. The firm is an active investor in both early and late-stage companies and typically makes investments ranging from $1M to over $20M, depending on the company’s stage of development. The firm is open to global investment opportunities. 
 

The firm is primarily focused on therapeutics but has also invested in medical devices and diagnostics, remaining open to opportunities across these sectors. Within therapeutics, the firm considers all modalities and indications but is currently most interested in gene therapy, gene editing, and technologies addressing central nervous system (CNS) diseases. The firm invests in both pre-clinical and clinical-stage opportunities. 

The firm does not have specific company or management team requirements. The firm generally prefers to lead investment rounds and seek board representation but has also participated as a co-investor in syndicates. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A strategic corporate venture capital fund established by a full-fledged pharmaceutical company seeks to make equity investments in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies with clear potential to benefit cancer patients. Investment size is flexible depending on the deal, and the firm will also consider option-type investments and spin-outs in addition to pure equity investments. The firm is currently seeking focusing on opportunities in USA and Europe. 

The firm considers early-stage (generally research to pre-IND) first-in-class or new biology-based approaches in drug discovery and innovative platform technologies, particularly assets that have a strategic fit with the parent company’s pipeline. The firm invests across a wide range of modalities, including biologics, oncolytic viruses, small molecules, and, on an opportunistic basis, cell and gene therapies. The firm’s primary indication of interest is oncology, but it also evaluates opportunities in immunology, allergy, musculoskeletal, and orphan indications. 

While the firm is primarily focused on therapeutics, it may selectively review technologies in the medical device, diagnostic, or digital health sectors if there is strong strategic alignment. 

The firm seeks management teams with strong sector expertise. Leveraging deep oncology drug discovery and development capabilities, the firm provides financial resources and strategic support to help translate novel research and high-potential drug candidates into cornerstone products. The firm may request regional options or rights on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm based in the US has significant experience working with regulatory agencies to gain product approval in both the FDA and CFDA systems. Since its establishment, the firm has invested in over 60 companies and continues to actively pursue life science opportunities with its third fund, targeting 8-10 new investments per year. The firm typically participates in Seed to Series B financing rounds with check sizes between $500K and $2M and will consider companies based in the USA, Europe, and Asia. 

The firm takes an opportunistic approach and will evaluate all early-stage opportunities in therapeutics, medical devices, diagnostics, and digital health, provided the technology is highly disruptive. The firm’s strongest focus and expertise lie in the medical device sector. Within therapeutics, the firm considers pre-clinical and Phase I assets, while in medical devices and diagnostics, it is open to all device classes, including 510(k) and PMA, at both development and clinical trial stages. The firm has invested in companies ranging from those with validated prototypes to those already generating profits prior to investment. 

The firm seeks to partner with companies led by experienced management teams, ideally serial entrepreneurs with proven track records. The firm can lead or co-invest but generally prefers to lead rounds in medical device companies and will typically take a board seat in those cases. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

The firm is a venture capital firm with offices in Western Europe. The firm makes equity investments in early- to late-stage therapeutics, diagnostics, and medical device companies, typically allocating between €2 million and €10 million per investment. The firm invests exclusively in companies based in Central and Western Europe and is actively seeking new opportunities. 

The firm is highly opportunistic within the life sciences sector, focusing on therapeutics, diagnostics, and medical devices while also maintaining interest in digital health. In therapeutics, the firm targets products that are in clinical trials or ready to enter Phase I. In medical devices, the firm seeks technologies that are CE Mark ready. While open across subsectors and indications, the firm does not invest in cosmetics or dental devices. The firm strongly favors companies developing products that address significant unmet medical needs. 

In digital health, the firm prefers products that either have or are pursuing regulatory approval to monitor or treat medical conditions with unmet needs, typically incorporating both hardware and software components. The firm does not invest in consumer or lifestyle health products. The firm’s prior investments include companies developing small molecule therapeutics for women’s health and diagnostics targeting autoimmune, allergic, ophthalmic, inflammatory, and liver diseases, as well as a medical device company treating prostate cancer. 

The firm typically acts as a lead or co-lead investor in most financing rounds and requires a board seat in its portfolio companies. The firm seeks to partner with companies that have strong and experienced management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology